



## NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

TAKE NOTICE that the annual general meeting of shareholders (the “**Meeting**”) of BioMark Diagnostics Inc. (the “**Company**”) will be held at **130 – 3851 Shell Rd, Richmond, BC V6X 2W2 on Tuesday, December 20, 2022, at 9:00 a.m. (Vancouver Time)** for the following purposes:

1. to receive the audited consolidated financial statements of the Company for its fiscal year ended March 31, 2022, and the report of auditors thereon;
2. to fix the number of directors for the ensuing year at three (3);
3. to elect directors of Company for the ensuing year;
4. to appoint MNP LLP, Chartered Professional Accountants, as auditors for Company for the ensuing year and to authorize the directors to fix their remuneration;
5. to consider, and if deemed appropriate, to approve the Company’s Stock Option Plan (2022), as more particularly set out in the accompanying Management Information Circular; and
6. to transact such other business as may properly come before the Meeting.

Accompanying this Notice of Meeting are a Management Information Circular (“Circular”) and Proxy.

The Directors have fixed the close of business on November 4, 2022, as the record date for determination of shareholders entitled to notice of and the right to vote at the Meeting either in person or by proxy. A shareholder who is unable to attend the Meeting in person and who wishes to ensure that their shares will be voted at the Meeting, is requested to complete, date and execute the enclosed form of Proxy and deliver it to the Company’s transfer agent: COMPUTERSHARE INVESTOR SERVICES INC., Proxy Dept., 100 University Avenue, 8<sup>th</sup> Floor, Toronto, Ontario M5J 2Y1, FACSIMILE (within North America) 1-866-249-7775 (outside North America) (416) 263-9524, by fax, hand or by mail in accordance with the instructions set out in the form of Proxy.

The Company has elected to use the notice & access provisions (the “notice-and-access provisions”) under National Instrument 54-101 *Communication with Beneficial Owners of Securities of a Reporting Issuer* and National Instrument 51-102 *Continuous Disclosure Obligations* for the Meeting. Notice-and-access provisions are a set of rules developed by the Canadian Securities Administrators that reduce the volume of materials that must be physically mailed to shareholders by allowing the Company to post the information circular and any additional Meeting materials online. Shareholders will still receive this Notice of Meeting and a form of proxy (or voting instruction form if applicable) and may choose to receive a paper copy of the Circular. The Company will not use procedures known as “stratification” in relation to its use of the notice-and-access provisions in relation to the Meeting. Stratification occurs when a reporting issuer using notice-and-access provides a paper copy of the relevant Circular to some, but not all, shareholders with the notice package in relation to the relevant meeting.

The Meeting materials, including this Notice of Meeting, are available on the Company's website at <https://www.biomarkdiagnostics.com/> and will remain on the website for at least one full year from the date of this Notice of Meeting. The Meeting materials are also available under the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com).

Any shareholder who wishes to receive a printed paper copy of the Circular at no cost prior to the date of the Meeting must request a copy from the Company no later than December 9, 2022, by calling 604.370.0779, or by e-mailing [info@biomarkdiagnostics.com](mailto:info@biomarkdiagnostics.com). To obtain a paper copy of the Circular after the date of the Meeting, please contact the Company at 604.370.0779. The Company will send paper copies of the Circular to request shareholders at no cost to them within 10 calendar days of their request. In order to receive a copy of the Company's financial statements and MD&A, a shareholder may also contact the Company at the contact number above or by sending written request to the Company's head office address.

To obtain additional information about the notice-and-access provisions, a shareholder may contact the Company's transfer agent, Computershare Investor Services Inc., at the following toll-free number: 1-866-964-0492.

If you are a *registered shareholder* of the Company and are unable to attend the Meeting in person, please date and execute the accompanying form of proxy for the Meeting and deposit it with Computershare Investor Services Inc. at 100 University Avenue, 8th Floor, Toronto, Ontario, M5J 2Y1, Attention: Proxy Department, before 9:00 a.m. (Pacific time), on December 16, 2022, or no later than 48 hours (excluding Saturdays, Sundays and holidays) before any adjournment of the Meeting.

If you are a *non-registered shareholder* of the Company and receive these materials through your broker or another intermediary, please complete and return the request for voting instructions in accordance with the instructions provided to you by your broker or such other intermediary.

***Considering the ongoing COVID19 Pandemic and in the best interest of the health of all participants in the Company's Meeting, the Company respectfully asks that shareholders do not attend the Meeting in person. The Company requests that shareholders who wish to participate by listening to the Meeting, contact the Company by December 16, 2022, at [info@biomarkdiagnostics.com](mailto:info@biomarkdiagnostics.com) to be included in the telephone/video conference for the Meeting. The Company will arrange for participation for all shareholders who have requested it by December 16, 2022. However, the Company strongly recommends that shareholders vote by Proxy or VIF in advance to ease the voting tabulation at the Meeting by Computershare Investor Services Inc.***

DATED at Richmond, British Columbia on November 14, 2022

**ON BEHALF OF THE BOARD OF DIRECTORS**



---

**Rashid Ahmed Maula Bux**  
President, Chief Executive Officer and a Director